Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that company management will participate at the following upcoming investor conference:
December 2, 2019
· 1 min read